Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma

Clinical trial NCT06751134 · RECRUITING

Trial details

NCT number: NCT06751134
Sponsor: Nanjing Children's Hospital
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Neuroblastoma, Recurrent, Refractory

Start date: 2024-12-28
Primary completion: 2026-07-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.